Pitavastatin

HMG-CoA Reductase Inhibitor | Low-Interaction Statin

Pitavastatin is a newer-generation synthetic statin approved by the FDA in 2009 under the brand name Livalo. It distinguishes itself from other statins through its minimal cytochrome P450 metabolism, which translates to significantly fewer drug-drug interactions than atorvastatin, simvastatin, or lovastatin. This characteristic makes pitavastatin particularly attractive for individuals taking multiple medications or compounds simultaneously, a situation common among anabolic steroid users who may be running ancillaries, aromatase inhibitors, and other support compounds alongside their cycles. Unlike most statins that are heavily metabolized by CYP3A4 or CYP2C9, pitavastatin is primarily metabolized via glucuronidation by UGT1A3 and UGT2B7, with negligible involvement of CYP enzymes. This means compounds and medications that inhibit or induce CYP3A4 do not meaningfully alter pitavastatin blood levels. Clinically, pitavastatin delivers LDL reductions of 38-45% at its standard 2-4 mg dose range, placing it in the moderate-to-high intensity category. Perhaps most notably, pitavastatin carries the lowest risk of new-onset diabetes among all statins, a finding consistently demonstrated across multiple clinical trials and meta-analyses including the LIVES study and J-PREDICT trial. This makes it an especially prudent choice for individuals with pre-existing insulin resistance or those using compounds known to impact glucose metabolism.